Wed.Jun 05, 2024

article thumbnail

Researchers Find Shared Multiomic Molecular Dysregulations in Brains With PTSD and MDD

Pharmacy Times

The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.

149
149
article thumbnail

Finland to offer bird flu vaccine to select groups of people, a possible global first

STAT

LONDON — Finland is preparing to offer vaccines to people at risk of exposure to an avian influenza strain spreading among farmed and wild animals, health officials there said, potentially becoming the first country to take such a step as concerns about the threat the virus poses to people intensify. The vaccine campaign will be limited, with doses set to be available to groups including poultry farmers, veterinarians, scientists who study the virus, and people who work on fur farms housi

Vaccines 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Study: Tezepelumab Reduces Annual Rates of Exacerbations Related to COPD

Pharmacy Times

For patients with a blood eosinophil count of 150 cells/µL or greater, tezepelumab had a significant reduction of approximately 37% in the rate of moderate or severe exacerbations.

131
131
article thumbnail

These are the bird flu questions that influenza and animal scientists desperately want answered

STAT

Ten weeks after government scientists discovered that H5N1 bird flu was sickening dairy cattle in the United States, many of the mysteries surrounding what is happening on affected farms remain just that. Widespread reluctance on the part of farmers to allow scientists — government or otherwise — onto their premises to study spread of the virus among infected cows has created a frustrating lack of understanding of the dynamics of this outbreak.

145
145
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Increased Social Vulnerability Accounted for Decrease in Diabetes Control

Drug Topics

In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers addressed the association between social vulnerability and glycemic control in patients with diabetes.

112
112
article thumbnail

Opinion: 100,000 models show that not much was learned about stopping the Covid-19 pandemic

STAT

In the midst of the Covid-19 pandemic, scientists and public health institutions made bold claims about the effectiveness of various policy responses such as closing schools and banning public gatherings. These claims shaped government responses and had enormous effects on the lives of billions of people around the world. Are those claims supported by data?

145
145

More Trending

article thumbnail

STAT+: Student group that ranked med schools over industry conflicts votes to accept pharma funding

STAT

An organization devoted to educating future doctors about conflicts of interest will now accept industry funding due to financial stress, prompting outrage from former members who argue the decision will undermine its mission. In a little-noticed move, the American Medical Student Association board recently approved an emergency resolution to accept money from drug and device makers, as well as health insurers, so long as funding does not exceed 25% of its operating budget.

Insurance 144
article thumbnail

Appeals court upholds ruling barring former Express Scripts chief from joining CVS

Fierce Healthcare

A federal appeals court has upheld an injunction preventing the former head of Express Scripts from taking an executive role at CVS Health. | A federal appeals court has upheld an injunction preventing the former head of Express Scripts from taking an executive role at CVS Health.

122
122
article thumbnail

STAT+: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits

STAT

Gilead Sciences agreed in principle to pay $40 million to more than 2,600 AIDS patients who claimed the company boosted profits by marketing an HIV drug without disclosing harmful side effects while delaying development of a safer alternative treatment. The agreement caps a dispute that cast a harsh spotlight on a strategy that Gilead allegedly used to maximize revenues and extend the lifespan of a best-selling product, but at the expense of patients.

142
142
article thumbnail

Examining Excessive Weight Gain, Impact of High Insulin Levels in Breast Cancer

Drug Topics

Posters presented at ENDO 2024 investigated excessive weight gain in breast cancer survivors and how high insulin levels impact outcomes for Black women with an aggressive form of the disease.

98
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study

STAT

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year. The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was ​​54.9%, 51.3%, and 51.0% from the lowest to highest doses.

141
141
article thumbnail

First rare disease therapies chosen for FDA START programme

pharmaphorum

An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen its first pilot programme candidates.

FDA 116
article thumbnail

Withdrawal symptoms hit one in six patients stopping antidepressants, review finds

STAT

The moment when a person stops taking their antidepressant is fraught. Not only can patients see their psychiatric symptoms return, but they can experience a wide variety of new symptoms in the days and weeks immediately following the medication change. Symptoms like nausea and headache can be manageable, and typically begin and end within days of ending the medication.

131
131
article thumbnail

Coverage pathways for psychedelic therapies

Fierce Healthcare

This week on "Podnosis," we explore therapeutic psychedelics. | This week on "Podnosis," we explore therapeutic psychedelics. Noah Tong from Fierce Healthcare sat down with Kim Chew, Senior Counsel at Husch Blackwell, to discuss the accessibility challenges in this promising but complex space.

114
114
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: As Washington mulls new AI rules, startup leaders want a seat at the table

STAT

WASHINGTON — In San Francisco, Y Combinator’s firebrand chief executive Garry Tan is one of the startup economy’s most recognizable figures. Well before he became the leader of the coveted startup accelerator that bred global brands like Airbnb, Stripe and OpenAI, Tan was a self-made founder who sold his own company to Twitter. But here in the nation’s political capital, Tan is far less known.

119
119
article thumbnail

From one juggernaut to another: Lilly CFO Anat Ashkenazi takes same role at tech giant Alphabet

Fierce Pharma

After 23 years at Eli Lilly, including the last three as its CFO, Anat Ashkenazi is leaving to take the same role at Google's parent company Alphabet.

116
116
article thumbnail

STAT+: Appeals court overturns Sutter Health’s victory in $400 million antitrust case

STAT

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.

Insurance 114
article thumbnail

Lilly touts fibrosis win as it pads case for tirzepatide in MASH

Fierce Pharma

Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease. | Back in February, Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in patients with fatty liver disease.

106
106
article thumbnail

STAT+: FTC loses its bid to block Novant’s hospital merger in North Carolina

STAT

A federal judge ordered Wednesday that Novant Health can move forward with its plan to buy two North Carolina hospitals, denying the Federal Trade Commission’s request for an injunction. The FTC sued to block the deal in January, arguing that it would give Novant control of more than 65% of the region’s inpatient market. The case, one seeking to block nearby hospitals from merging and creating an even more powerful dominant player, is the FTC’s bread and butter.

Hospitals 112
article thumbnail

Poor Cardiovascular Health in Women Linked to Cognitive Decline in Midlife

Pharmacy Times

Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.

131
131
article thumbnail

Judge denies FTC's preliminary bid to block Novant, CHS' $320M hospital deal

Fierce Healthcare

Novant Health and Community Health Systems (CHS) will be permitted to consummate their contested $320 million hospital deal, though the pair still face some regulatory uncertainty following the dea | U.S. District Judge Kenneth Bell wrote that the two-hospital transaction has "at least as much likelihood of competitive benefits as it does competitive harm.

Hospitals 111
article thumbnail

ASCO: KRAS upstarts set their sights on NSCLC market

pharmaphorum

KRAS inhibitors from Eli Lilly, Genfleet, and InxMed make their case for use in NSCLC at ASCO, as they case down Amgen and Bristol-Myers Squibb's market drugs

116
116
article thumbnail

Appeals court revives $411M antitrust class action against Sutter Health

Fierce Healthcare

An appellate court panel has resuscitated a nine-figure antitrust class-action lawsuit against Sutter Health, ruling Tuesday that a 2022 jury was given improper instructions and that a new trial mu | The decadelong case had been unanimously ruled in the nonprofit system's favor back in 2022. A 2-1 panel has now reversed the judgment and remanded for a new trial.

111
111
article thumbnail

Gilead, Ipsen build the case for their PBC drugs at EASL

pharmaphorum

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term efficacy and safety.

FDA 111
article thumbnail

Opinion: As states legalize recreational marijuana use for adults, they must prioritize protecting kids

STAT

Thirty-eight states and the District of Columbia have legalized the use of marijuana products for medical use, and 24 of those have legalized it for adult recreational use. As states establish their legal marijuana markets, their main priority — before addressing concerns around tax revenue, social equity issues, illegal markets, or anything else — should be ensuring that young people are protected from exposure to marijuana and can’t access it.

104
104
article thumbnail

Regenerative cell therapy biotech uses IPO to blast into human trials

PharmaVoice

Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

119
119
article thumbnail

STAT+: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more

STAT

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

FDA 101
article thumbnail

When is the best time to take milk thistle?

The Checkup by Singlecare

Milk thistle ( Silybum marianum ) is a tall plant with purple flowers that belongs to the daisy family. Originally native to Europe, milk thistle can now be found all over the world. The plant’s main active ingredient, an antioxidant called silymarin , is responsible for many of the health benefits of milk thistle. Because of this, milk thistle and silymarin are often used interchangeably to refer to the same plant.

article thumbnail

Cyberattack disrupts patient care at London hospitals

pharmaphorum

NHS hospitals in London have declared a critical incident caused by a ransomware attack on a pathology services provider, leading to cancelled procedures and patients having to be transferred to different care providers. The attack on Synnovis has had an impact on patient care at Guy’s and St Thomas’ and King’s College Hospital NHS Foundation Trusts, as well as GP services in southeast London, according to an NHS England statement.

article thumbnail

Testing begins for a new form of PrEP

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Jason Mast here filling in for Elaine. We’ve got a dramatic vote on psychedelic therapy, record drug shortages, bad (maybe?) news for Biomarin, and a new kind of PrEP.

article thumbnail

PHTI backs virtual therapies for musculoskeletal disorders

pharmaphorum

PHTI's latest report finds that digital therapies for musculoskeletal conditions like low back pain can deliver clinically meaningful benefits

113
113
article thumbnail

Study: Prevalence of Diabetes Expected to Increase by 59.7% in 2025

Pharmacy Times

Body mass index is the main driver of type 2 diabetes globally, accounting for 52.2% of disability-adjusted life years.

127
127
article thumbnail

Opinion: Listen: Among pregnant people, active treatment for addiction shouldn’t trigger a call to child protective services

STAT

Methadone and buprenorphine, both FDA-approved drugs, are considered the gold standard for treating opioid use disorder. They are so effective, in fact, that they are considered nearly curative for people who use them as prescribed. But a multitude of social and physical barriers to access mean that only about 20% of people who could benefit from these medicines have access to them.

FDA 97
article thumbnail

Biologic demonstrates durable tumour regression in rectal cancer

European Pharmaceutical Review

New clinical data from a Phase II trial for rectal cancer has revealed a 100 percent clinical complete response rate following first-line therapy with Jemperli (dostarlimab-gxly). These findings from GSK reflect outcomes from 42 patients with mismatch repair deficient (dMMR) locally advanced rectal cancer who finished the treatment. The trial investigated the therapy as an alternative to surgery.